Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting

Tumori. 2014 May-Jun;100(3):358-62. doi: 10.1700/1578.17228.

Abstract

We present an overview of a number of key clinical studies in infiltrating gliomas presented at the 2013 Society for Neuro-Oncology and World Federation of Neuro-Oncology joint meeting. This review focuses on efficacy results, including quality of life studies, from larger clinical trials in both high- and low-grade infiltrating gliomas.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / genetics
  • Brain Neoplasms / pathology
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / therapy*
  • Clinical Trials as Topic
  • Congresses as Topic
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / therapeutic use
  • Glioma / drug therapy
  • Glioma / genetics
  • Glioma / pathology
  • Glioma / radiotherapy
  • Glioma / therapy*
  • Humans
  • Medical Oncology / trends*
  • Neoplasm Grading
  • Neurology / trends*
  • Quality of Life*
  • Randomized Controlled Trials as Topic
  • Societies, Medical
  • Temozolomide
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab
  • Dacarbazine
  • Temozolomide